Amgen, Inc. (NASDAQ:AMGN)
A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
This company will outperform the S&P because is was practicaly the original Biotech company. If there is going to be an advance in Biotechnology, this is the company to look for it in. Even though you shouldn't go for the big companies, this is the time to pick because there is going to be an advance in biotech very soon.
Recs
There are currently 650 AMGN shares in my "fund" with break-even of around 59.13 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
Recs
AMGN is a canary stock - cheep, cheep, cheep. Well-positioned as a trading stock given its volatility.
Recs
Biotech will soon lead the market, and it dominates my intermediate-term portfolio. Amgen is going to get legs again with new growth products, then LOOKOUT!
Recs
Could a dividend be in the future?
I smell one coming......
Recs
Good size company at market cap of 49.30 billion. Price/earnings of 11.04 is pretty low relative to industry. Total long term debt is a bit much at 13.36 billion, but when taken in consideration with its market cap, and its total cash of 17.42 billion, this seems alright. Attractive collaborative arrangements with Pfizer and GlaxoSmithKline. In addition, return on invested capital (ROIC) is impressive, at over 22 percent.
Recs
Looks fundamentally undervalued
Recs
Great value...Biotechnology stock trading well below it s 52 week high
Recs
AMGN's Product line continues to expand.. no reason to bet against this winner!
Recs
good cash balances
Recs
Underperform
Recs
Biotech watchlist
Recs
Will need to buy a company to enrich near-term pipeline outside of Xgeva/Prolia which won't contribute much to the bottom line for the next year or so... this will leave revenues flat. Entering "big pharma"-like phase... not a growth stock in the near term...
Recs
Go long and strong and grab anything under $60.
Recs
If 2011's revenue and earnings are stagnant, where exactly is the growth coming from to propel the shares in the next 12 months?
Recs
a biotech stock trading at big pharma prices.
Recs
Recs
banking on upcoming phase III results
Recs
The best buy in biotech
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 334 : 1 2 3 4 5 6 7 8 9 10 Next »